

Special Issue

Biofluid-Based Metabolomics for Biomarker Discovery

Message from the Guest Editor

Nowadays, advancements in omics technologies allow the routine generation of high-quality and high-content data from any biological sample, among which metabolomics has quickly become a major screening tool in the field of biomarker discovery due to being the product of gene expression and protein activity and, thus, closest to the phenotype. Both precision health and precision medicine strategies rely on biomarkers to assess disease risk, detect early preclinical conditions, assess disease progression and monitor treatment response. This Special Issue of *Metabolites* is devoted to biomarker discovery in biofluids using metabolomics technologies, topics covered including, but not limited to, the exploration of novel biological matrixes and sampling procedures, methodological development (sample preparation and data acquisition), the improvement of analysis workflows (data annotation and machine learning approaches) as well as advances in biomarker prioritization, both clinical and translational studies being equally desirable. Herein, the definition of metabolites is broad and includes xenobiotics, complex lipids and lipid mediators.

Guest Editor

Dr. K vin Contrepois

Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA

Deadline for manuscript submissions

closed (15 May 2023)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/110007

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).